JCR Pharmaceuticals
4552.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥40.3bn | ¥33.1bn | ¥42.9bn | ¥34.3bn | ¥51.1bn | ¥30.1bn |
| Operating income | ¥555m | −¥6.2bnr | ¥7.5bn | ¥5.0bn | ¥19.9bn | ¥8.3bn |
| Ordinary income | ¥1.2bn | −¥7.0bnr | ¥7.3bn | ¥5.4bn | ¥20.5bn | ¥8.5bn |
| Net income (owners) | ¥2.2bn | −¥4.5bnr | ¥5.5bn | ¥3.8bn | ¥14.5bn | ¥6.9bn |
| Total assets | ¥109.2bn | ¥104.8bnr | ¥102.2bn | ¥94.9bn | ¥97.1bn | ¥73.8bn |
| Net assets / equity | ¥47.4bn | ¥47.7bnr | ¥56.5bn | ¥52.4bn | ¥51.1bn | ¥38.6bn |
| Operating cash flow | −¥135m | −¥5.8bnr | ¥9.3bn | −¥5.5bn | ¥9.3bn | ¥10.3bn |
| EPS (basic) | ¥17.87 | ¥-36.02r | ¥44.13 | ¥30.35 | ¥117.26 | ¥55.81 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 8
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | AnnualAmended | 205 figures · EDINET |
| 2025-04-01 → 2026-03-31 | Annual | 205 figures · EDINET |
| 2024-04-01 → 2025-03-31 | AnnualAmended | 205 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 205 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 207 figures · EDINET |
| 2022-04-01 → 2023-03-31 | AnnualAmended | 207 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 207 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 207 figures · EDINET |
21 more reports are still being processed.